Peay HL, Fischer R, Mange B, Paquin RS, Smith EC, Sadosky A, Russo L, Ricotti V, Rensch C, Morris C, Martin AS, Ganot A, Beaverson K, Mansfield C. Patients' and caregivers' maximum acceptable risk of death for non-curative gene therapy to treat Duchenne muscular dystrophy. Mol Genet Genomic Med. 2021 May;9(5):e1664. doi: 10.1002/mgg3.1664
Mellor R, Lancaster K, Ritter A. Systematic review of untreated remission from alcohol problems: estimation lies in the eye of the beholder. J Subst Abuse Treat. 2019 Jul;102:60-72. doi: 10.1016/j.jsat.2019.04.004
Ling W, Nadipelli VR, Solem CT, Ronquest NA, Yeh YC, Learned SM, Mehra V, Heidbreder C. Effects of monthly buprenorphine extended-release injections on patient-centered outcomes: a long-term study. J Subst Abuse Treat. 2019 Mar;110:1-8. doi: 10.1016/j.jsat.2019.11.004
Wilson MR, Gutierrez B, Offord S, Blanchette CM, Eramo A, Earnshaw SR, Kamat SA. Inpatient resource use and costs associated with switching from oral antipsychotics to aripiprazole once-monthly for the treatment of schizophrenia. Drugs Context. 2016 Mar 11;5:212273. doi: 10.7573/dic.212273